More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

The results of PwC’s 22nd annual survey of 1,300-plus CEOs, which were launched this week at the World Economic Forum Annual Meeting in Davos, Switzerland, shows that nearly 30% believe that global economic growth will decline in the next 12...

Last year (2018) was a record-setting year for approvals of new molecular entities (NMEs) by the FDA with 59 NMEs approved. DCAT Value Chain Insights examines the 2018 NME approvals, the product mix between small molecules and biologics, and which...

As the industry enters a new year, what will be key issues shaping the pharmaceutical industry in 2019? Coming off a record-setting year for new molecular entities approved by the FDA in 2018, will the industry be able to meet a new innovation bar...

As 2018 comes to a close, what are key trends and emerging areas of interest for the pharmaceutical industry overall and in manufacturing? From new business models in healthcare delivery, to drug pricing, to digital transformation, to new...

Refining business strategies to respond to changing market conditions is a constant in any industry, including the pharmaceutical industry. As the industry enters the final month of 2018, which pharmaceutical company CEOs have made the mark thus...

What were the top developments shaping the pharmaceutical industry overall and the pharma manufacturing value chain in 2018? Takeda’s pending $62-billion acquisition of Shire, Cambrex’s $425-million acquisition of Halo Pharmaceuticals, a...

Emerging markets represent both opportunity and challenges for pharmaceutical companies. Risk management is an important component of any sourcing program, but with rising trade tensions and geopolitical uncertainty, managing supply lines and...